@article {Perotti2020.05.26.20113373, author = {Cesare Perotti and Fausto Baldanti and Raffaele Bruno and Claudia Del Fante and Elena Seminari and Salvatore Casari and Elena Percivalle and Claudia Glingani and Valeria Musella and Mirko Belliato and Martina Garuti and Federica Meloni and Marilena Frigato and Antonio Di Sabatino and Catherine Klersy and Giuseppe De Donno and Massimo Franchini}, title = {Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial}, elocation-id = {2020.05.26.20113373}, year = {2020}, doi = {10.1101/2020.05.26.20113373}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {BACKGROUND Hyperimmune plasma from Covid-19 convalescent is a potential treatment for severe Covid-19.METHODS We conducted a multicenter one arm proof of concept interventional study. Patients with Covid-19 disease with moderate-to-severe Acute Respiratory Distress Syndrome, elevated C-reactive Protein and need for mechanical ventilation and/or CPAP were enrolled. One to three 250-300 ml unit of hyperimmune plasma (neutralizing antibodies titer >=1:160) were administered. Primary outcome was 7-days hospital mortality. Secondary outcomes were PaO2/FiO2, laboratory and radiologic changes, as well as weaning from mechanical ventilation and safety.RESULTS The study observed 46 patients from March, 25 to April, 21 2020. Patients were aged 63, 61\% male, 30 on CPAP and 7 intubated. PaO2/FiO2 was 128 (SD 47). Symptoms and ARDS duration were 14 (SD 7) and 6 days (SD 3). Three patients (6.5\%) died within 7 days. The upper one-sided 90\%CI was 13.9\%, allowing to reject the null hypothesis of a 15\% mortality. PaO2/FiO2 increased by 112 units (95\%CI 82 to142) in survivors, the chest radiogram severity decreased in 23\% (95\%CI 5\% to 42\%); CRP, Ferritin and LDH decreased by 60, 36 and 20\% respectively. Weaning from CPAP was obtained in 26/30 patients and 3/7 were extubated. Five serious adverse events occurred in 4 patients (2 likely, 2 possible treatment related).CONCLUSIONS Hyperimmune plasma in Covid-19 shows promising benefits, to be confirmed in a randomized controlled trial. This proof of concept study could open to future developments including hyperimmune plasma banking, development of standardized pharmaceutical products and monoclonal antibodies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT 04321421 March 23, 2020Funding Statementno funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:approved by the local Ethical Committee on March 17th, 2020 (Number n. 20200027967)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesaggregated dta from corresponding author}, URL = {https://www.medrxiv.org/content/early/2020/05/29/2020.05.26.20113373}, eprint = {https://www.medrxiv.org/content/early/2020/05/29/2020.05.26.20113373.full.pdf}, journal = {medRxiv} }